EMBC
Embecta Corp. NASDAQ Listed Mar 22, 2022$3.60
After hrs
$3.62
-0.55%
Mkt Cap $213.6M
52w Low $3.45
1.2% of range
52w High $15.55
50d MA $8.97
200d MA $11.82
P/E (TTM)
5.6x
EV/EBITDA
6.9x
P/B
—
Debt/Equity
-2.2x
ROE
-22.8%
P/FCF
4.5x
RSI (14)
—
ATR (14)
—
Beta
1.10
50d MA
$8.97
200d MA
$11.82
Avg Volume
872.6K
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
300 Kimball Drive · Parsippany, NJ 07054 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2026 | BMO | 0.67 | 0.71 | +6.0% | 10.47 | +0.5% | +3.8% | +3.8% | -1.6% | -1.7% | -3.9% | — |
| Nov 25, 2025 | BMO | 0.70 | 0.50 | -28.6% | 13.58 | -1.6% | -7.4% | -7.4% | -6.0% | -9.8% | -9.4% | — |
| Aug 8, 2025 | BMO | 0.46 | 1.12 | +146.2% | 12.28 | +1.0% | +3.7% | +3.7% | +8.5% | +13.5% | +12.9% | — |
| May 9, 2025 | BMO | 0.66 | 0.70 | +6.1% | 11.97 | +4.1% | +3.7% | +3.7% | +4.4% | -3.2% | -2.6% | — |
| Feb 6, 2025 | BMO | 0.45 | 0.65 | +44.4% | 17.73 | -0.1% | -1.7% | -1.7% | -1.3% | -1.3% | -6.3% | — |
| Nov 26, 2024 | BMO | 0.36 | 0.45 | +25.0% | 18.70 | +4.7% | +10.1% | +10.1% | +11.4% | +10.3% | +9.3% | — |
| Aug 9, 2024 | BMO | 0.48 | 0.74 | +54.2% | 15.39 | -0.3% | -4.2% | -4.2% | -3.7% | -4.2% | -5.3% | — |
| May 9, 2024 | BMO | 0.43 | 0.67 | +55.8% | 14.16 | +2.8% | +0.6% | +0.6% | +0.1% | +3.1% | -2.9% | — |
| Feb 9, 2024 | BMO | 0.45 | 0.61 | +35.6% | 16.26 | -0.1% | -7.9% | -7.9% | -12.4% | -10.6% | -9.1% | — |
| Nov 21, 2023 | BMO | 0.42 | 0.59 | +40.5% | 17.06 | +2.4% | +3.3% | +3.3% | +2.5% | +1.9% | +2.6% | — |
| Aug 8, 2023 | BMO | 0.46 | 0.69 | +50.0% | 22.17 | -0.5% | -3.0% | -3.0% | -6.1% | -6.0% | -7.1% | — |
| May 12, 2023 | BMO | 0.50 | 0.75 | +50.0% | 30.69 | +0.4% | -6.5% | -6.5% | -6.0% | -8.9% | -7.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6 | BTIG Research | Downgrade | Buy → Neutral | — | $3.90 | $3.99 | +2.3% | -8.7% | -7.7% | — | — | — |
| Apr 13 | Mizuho | Maintains | Neutral → Neutral | — | $8.85 | $8.81 | -0.5% | +4.6% | +6.9% | +8.6% | +7.5% | +10.5% |
| Feb 6 | BTIG | Maintains | Buy → Buy | — | $10.47 | $10.52 | +0.5% | +3.8% | -1.6% | -1.7% | -3.9% | -4.5% |
| Sep 5 | BTIG | Maintains | Buy → Buy | — | $14.49 | $14.48 | -0.1% | +3.2% | +1.1% | +5.1% | +3.3% | +5.7% |
| Jul 16 | Mizuho | Maintains | Neutral → Neutral | — | $9.58 | $9.68 | +1.0% | +1.8% | +2.8% | +2.1% | +7.4% | +11.6% |
| May 23 | Mizuho | Maintains | Neutral → Neutral | — | $10.51 | $10.40 | -1.0% | +2.0% | +7.1% | +0.4% | -0.5% | +0.2% |
| Nov 27 | BTIG | Upgrade | Neutral → Buy | — | $18.70 | $19.57 | +4.7% | +10.1% | +11.4% | +10.3% | +9.3% | +9.6% |
| Jul 15 | Morgan Stanley | Maintains | Underweight → Underweight | — | $13.17 | $12.90 | -2.1% | -2.5% | +0.2% | +3.3% | +1.4% | +0.0% |
| May 10 | Morgan Stanley | Maintains | Underweight → Underweight | — | $14.16 | $14.56 | +2.8% | +0.6% | +0.1% | +3.1% | -2.9% | +0.3% |
| Nov 22 | Morgan Stanley | Maintains | Underweight → Underweight | — | $17.06 | $17.47 | +2.4% | +3.3% | +2.5% | +1.9% | +2.6% | +6.1% |
| Oct 18 | Morgan Stanley | Maintains | Underweight → Underweight | — | $15.59 | $15.08 | -3.3% | -1.2% | -1.7% | -0.6% | -0.5% | +5.3% |
| Aug 24 | Morgan Stanley | Maintains | Underweight → Underweight | — | $17.65 | $17.28 | -2.1% | -4.0% | -2.9% | -1.1% | +2.6% | +4.0% |
| Jul 18 | Morgan Stanley | Maintains | Underweight → Underweight | — | $20.22 | $20.10 | -0.6% | -0.8% | -2.3% | -2.3% | +1.1% | +0.2% |
| May 15 | Morgan Stanley | Maintains | Underweight → Underweight | — | $30.69 | $30.80 | +0.4% | -6.5% | -6.0% | -8.9% | -7.3% | -11.9% |
| Jan 6 | Morgan Stanley | Downgrade | Equal Weight → Underweight | — | $25.14 | $24.13 | -4.0% | -0.4% | -2.5% | -2.4% | -4.6% | -7.8% |
| Dec 21 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $27.40 | $27.40 | +0.0% | +2.4% | +1.9% | +0.4% | -2.1% | -5.7% |
| Oct 11 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $28.38 | $28.41 | +0.1% | -1.3% | -1.0% | +2.3% | +1.4% | +3.3% |
| Sep 8 | BTIG | Maintains | Neutral → Neutral | — | $32.02 | $31.35 | -2.1% | +1.3% | +1.2% | +3.3% | -0.4% | +1.5% |
| Aug 16 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $33.42 | $33.20 | -0.7% | -3.3% | -2.2% | -0.1% | +0.0% | -1.6% |
| Aug 1 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $29.43 | $28.69 | -2.5% | +0.3% | +2.8% | +1.5% | +0.6% | +5.0% |
| Jun 21 | BofA Securities | Maintains | Underperform → Underperform | — | $28.26 | $27.01 | -4.4% | -4.5% | +0.5% | -4.4% | -4.9% | -4.5% |
No insider trades available.
8-K · 2.02
!! High
Embecta Corp. -- 8-K 2.02: Earnings Results
Embecta Corp. reported Q1 2026 earnings results, providing investors with updated financial performance and operational metrics for the quarter ended March 31, 2026.
May 5
8-K · 1.01
!! High
Unknown — 8-K 1.01: Material Agreement
This standard SEC boilerplate about furnishing documents upon request carries no material implications for EMBC's stock, as it merely describes routine regulatory compliance procedures rather than substantive business developments.
Mar 20
8-K
Embecta Corp. -- 8-K Filing
Embecta Corp. shareholders approved executive compensation packages for named officers through say-on-pay voting, indicating investor support for management's remuneration structure.
Feb 13
8-K
Embecta Corp. -- 8-K Filing
Embecta is prioritizing strengthening its injection product market leadership while expanding its portfolio and reducing debt to improve financial flexibility.
Feb 5
Data updated apr 25, 2026 7:03am
· Source: massive.com